ActiTrexx

Autoimmune diseases, auto-inflammatory diseases, and allergies are associated with overshooting T cell mediated immune reactions. Among these, Graft-versus-Host Disease (GvHD), a severe and potentially life-threatening complication after stem cell transplantation, faces a high unmet medical need. 

ActiTrexx is a clinical phase biotech company, developing a platform of patent-protected cellular and biologic therapies targeting the root-cause of overshooting immune responses, thereby decreasing the need for immunsuppressants. ActiTrexx products activate Treg in vivo and ex vivo. With their cellular lead product Actileucel their goal is to prevent GvHD at an early stage after stem cell transplantation and to provide a curative approach. In 2024, ActiTrexx marked a significant milestone by treating the first patient with Actileucel. Actileucel's groundbreaking characteristic is its ultra-fast manufacturing process, which allows readiness of the cell therapy within 24 hours. Furthermore, Actileucel will pioneer as the first unmatched cell therapy sourced from a third-party donor.